Long-term Study of Immune Response to a Booster Dose of MVA-BN Vaccine in Men on HIV Pre-Exposure Prophylaxis

What this Trial Is About

Researchers are studying the long-term immune response to a booster dose of the MVA-BN vaccine, which is designed to prevent mpox, a viral disease caused by the MPXV virus. This research focuses on men who have sex with men MSM using HIV pre-exposure prophylaxis PrEP, a key group at risk. The study is observational and aims to provide more information on how durable the vaccines protection is after a booster dose, following recommendations due to recent outbreaks and public health concerns worldwide. Participants in this study have previously received two doses of the MVA-BN vaccine and are eligible for a booster dose as per health guidelines. The study will observe these individuals over time without assigning treatments, monitoring their immune responses after the booster dose. The trial will track immune system markers and any mpox infections to understand the vaccines long-term effects. During the study, participants will be followed for up to 24 months, with evaluations of their immune response and safety after receiving the booster dose. Researchers will collect data on antibody levels at 12 and 24 months, observe the pattern of immune response, and document any cases of mpox infection. The study involves regular medical monitoring and aims to gather detailed information about how the booster dose supports immunity in this population.

Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine